Robert Hombach J.'s Insider Trades & SAST Disclosures
Robert Hombach J.'s most recent trade in Henry Schein Inc. was a trade of 2,844 Common Stock par value $0.01 per share done . Disclosure was reported to the exchange on March 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Hombach J..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Henry Schein Inc.
|
Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 2,844 | 2,844 (0%) | 0% | 0 | Common Stock par value $0.01 per share | |
|
Embecta Corp
|
Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 13,839 | 39,749 | - | 0 | Common Stock | |
|
Biomarin Pharmaceutical In...
|
Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 4,720 | 35,220 (0%) | 0% | 0 | Common Stock | |
|
Embecta Corp
|
Robert Hombach J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 11,455 | 24,903 | - | 0 | Common Stock | |
|
Biomarin Pharmaceutical In...
|
Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 4,190 | 30,500 (0%) | 0% | 0 | Common Stock | |
|
Biomarin Pharmaceutical In...
|
Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 4,980 | 26,310 (0%) | 0% | 0 | Common Stock | |
|
Embecta Corp
|
Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 6,024 | 6,024 | - | 0 | Common Stock | |
|
Carmax Inc
|
Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2021 | 1,308 | 7,766 (0%) | 0% | 0 | Common Stock | |
|
Biomarin Pharmaceutical In...
|
Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 5,120 | 21,330 (0%) | 0% | 0 | Common Stock | |
|
Carmax Inc
|
Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2020 | 2,021 | 6,458 (0%) | 0% | 0 | Common Stock | |
|
Biomarin Pharmaceutical In...
|
Robert J. Hombach | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2020 | 4,300 | 16,210 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges